Procyon is a new cancer diagnostics spinout from Queen Mary University of London which has just completed an oversubscribed ...

Rapalink-1, the new drug studied by the team, is a next-generation TOR inhibitor currently under investigation for cancer therapy. The researchers found that rapalink-1 not only slowed aspects of ...

While the study did not find a “hyperrealism effect” from the AI voices, it did find that voice clones can sound as real as ...

Announced at the House of Lords, findings from the paper in The Lancet: Healthy Longevity demonstrate that the intervention, ...

A podcast that uncovers London’s hidden Cockney Yiddish culture, hosted by Queen Mary historians Professor Nadia Valman and ...

Queen Mary University of London has partnered with the MassChallenge startup accelerator to offer a new route to impact for ...

The pioneering study uses a new approach to detect the presence of circulating tumour DNA (ctDNA) to accurately identify ...

Queen Mary University of London and Barking and Dagenham Council have launched a major new partnership to tackle local health and wellbeing challenges in the community.

Queen Mary University of London and Barking and Dagenham Council have launched a major new partnership to tackle local health ...

Accommodation Alumni Schools and Institutes Careers and Enterprise Collaborate with us Contact Events Global How to find us International students Jobs Library MyQMUL New students News Order a ...